Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
NLTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsNeoleukin Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Neoleukin Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Neoleukin Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Neoleukin Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NLTX revenue · 4 questionsNLTX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Neoleukin Therapeutics, Inc. SEC filings · GAAP · Neoleukin Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026